"Pharmaceutical headlinejun" more than 5000 products suspended hanging net another round of market shuffling will begin.

(2020/07/07) Patient death! Clinical trials for the treatment of MM by generic CAR-T were called off by the FDA; the top 3 "barefoot" varieties in the field of 13 new drugs led by Xinlitai in the field of chronic disease spent on collection and release, and the list of drug sales published by a number of national varieties fell out of the listCellectis is a biopharmaceutical company focused on developing gene-editing-based allogeneic CAR-T cell (UCART) immunotherapyRecently, the company announced that its clinical trial MELANI-01 has been suspended by the U.SFDAThe company's shares fell 18 percent on the newsCellectis is working closely with the FDA to meet safety requirementson June 18, this year, the State Administration of Health Care released the "Health Care Disease Diagnosis Related Sub-Group (CHS-DRG) Subdivision Group Program (VERSION 1.0)," which means that the Chinese characteristics of CHS-DRG before the landing of the cluster program is ready to be announcedthis is a determination shown by the NHS on payment-by-payment reformrecently, Fujian Province released the May and April drug price limit sunshine procurement drug sales amount of the top 20 listOf the 40 drugs published, 30 were products of multinational pharmaceutical companies, accounting for 75 per centIt's worth noting that Pfizer's phenyl sulphate and Sanofi's sulphate chlorpyrifos dropped to the top of the list compared to the same period last year, while Pfizer's Atofalstatin tablets dropped from the previous top five to 16th, rebounding slightly to 11th place in Mayanother round of market shuffling is about to beginsilence for many days, Xinlitai product line came good news, the first evaluation of the buck drug hydrochloric acid le cadiflat tablets, two class 1 new drugs declared clinical acceptanceMinnet data show that there are currently 11 varieties of Xinlitai over-ratedFor Grillo, Pivastatin, ground chlorrese he is expected to achieve rapid release through the third batch of the winning bidIn the research and development of innovative products, Xinlitai concentrate on the field of chronic diseases, mainly in the research of new drugs have 13, Ennashi he is expected to become the company's second patented drugWith the aging of the domestic and the harvest of innovative products, Xinlitai will be in the field of chronic disease stomping is expected to make a big splash in the slow-motion field not long ago, the Hubei Provincial People's Government's official website issued "to deal with the impact of the epidemic to further promote commercial consumption of a number of measures" on the B-class OTC (over-the-counter drug) sales made the latest provisions, which also means that in the future convenience stores to sell medicine procedures to simplify retail pharmacies and convenience stores "take your needs." since the expansion of the national siege of 4 plus 7, the collection of unselected drug prices to adjust or suspend the hanging network policy spread in various places From August 1, Jiangsu Province will also suspend or withdraw the hanging network processing of 5318 products, in addition to 12327 drugs in the province in accordance with the requirements of the adjustment of the price of the network, not so many products involved in Jiangsu this time? price is gradually becoming an important factor after the consistency evaluation and then the elimination of varieties 15% of non-small cell lung cancer patients in Europe and the United States and 30% of Asian patients carry Ingafr mutation, the market is huge Common EGFR mutant inhibitors (EGFR TKI) include the first generation of Gefitinib, Erlotinib, the second generation afatinib, Dacomitinib, the third generation osimerinib, and so on EGFR TKI significantly extends progression-free and total survival in the vast majority of Patients with EGFR mutations In particular, the third-generation drug Osimertinib not only inhibits most of the original hair type EGFR mutations, but also inhibits the acquired drug-resistant EGFR T790M mutation long-term clinical benefits still need to be further explored.